HLS Therapeutics (TSE:HLS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

HLS Therapeutics (TSE:HLS) had its target price hoisted by research analysts at Stifel Nicolaus from C$3.50 to C$4.00 in a research report issued on Wednesday,BayStreet.CA reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective suggests a potential downside of 11.50% from the stock’s previous close.

HLS Therapeutics Stock Performance

Shares of HLS opened at C$4.52 on Wednesday. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48. The stock has a market capitalization of C$100.56 million, a PE ratio of -4.53 and a beta of 1.07. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The stock has a 50-day simple moving average of C$4.18 and a 200-day simple moving average of C$3.80.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.